134 related articles for article (PubMed ID: 27565930)
1. Epidermal growth factor receptor mutations in adenocarcinoma in situ and minimally invasive adenocarcinoma detected using mutation-specific monoclonal antibodies.
Nakamura H; Koizumi H; Kimura H; Marushima H; Saji H; Takagi M
Lung Cancer; 2016 Sep; 99():143-7. PubMed ID: 27565930
[TBL] [Abstract][Full Text] [Related]
2. Identification of non-small-cell lung cancer with activating EGFR mutations in malignant effusion and cerebrospinal fluid: rapid and sensitive detection of exon 19 deletion E746-A750 and exon 21 L858R mutation by immunocytochemistry.
Kawahara A; Azuma K; Sumi A; Taira T; Nakashima K; Aikawa E; Abe H; Yamaguchi T; Takamori S; Akiba J; Kage M
Lung Cancer; 2011 Oct; 74(1):35-40. PubMed ID: 21444121
[TBL] [Abstract][Full Text] [Related]
3. Novel EGFR mutation-specific antibodies for lung adenocarcinoma: highly specific but not sensitive detection of an E746_A750 deletion in exon 19 and an L858R mutation in exon 21 by immunohistochemistry.
Seo AN; Park TI; Jin Y; Sun PL; Kim H; Chang H; Chung JH
Lung Cancer; 2014 Mar; 83(3):316-23. PubMed ID: 24412618
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical Localization of Wild-type EGFR, E746-A750 Frame Deletion in Exon 19, and L858R Point Mutation in Exon 21 in Triple-negative Breast Cancer.
Vora HH; Patel NA; Thakore PM; Shukla SN
Appl Immunohistochem Mol Morphol; 2015 Oct; 23(9):653-60. PubMed ID: 25789532
[TBL] [Abstract][Full Text] [Related]
5. Epidermal growth factor receptor mutation-specific immunohistochemical antibodies in lung adenocarcinoma.
Allo G; Bandarchi B; Yanagawa N; Wang A; Shih W; Xu J; Dalby M; Nitta H; To C; Liu N; Sykes J; Tsao MS
Histopathology; 2014 May; 64(6):826-39. PubMed ID: 24251405
[TBL] [Abstract][Full Text] [Related]
6. Application of a highly sensitive detection system for epidermal growth factor receptor mutations in plasma DNA.
Nakamura T; Sueoka-Aragane N; Iwanaga K; Sato A; Komiya K; Kobayashi N; Hayashi S; Hosomi T; Hirai M; Sueoka E; Kimura S
J Thorac Oncol; 2012 Sep; 7(9):1369-81. PubMed ID: 22858585
[TBL] [Abstract][Full Text] [Related]
7. EGFR mutant-specific immunohistochemistry has high specificity and sensitivity for detecting targeted activating EGFR mutations in lung adenocarcinoma.
Cooper WA; Yu B; Yip PY; Ng CC; Lum T; Farzin M; Trent RJ; Mercorella B; Clarkson A; Kohonen-Corish MR; Horvath LG; Kench JG; McCaughan B; Gill AJ; O'Toole SA
J Clin Pathol; 2013 Sep; 66(9):744-8. PubMed ID: 23757037
[TBL] [Abstract][Full Text] [Related]
8. Distinctive clinicopathological features of adenocarcinoma in situ and minimally invasive adenocarcinoma of the lung: A retrospective study.
Ishida H; Shimizu Y; Sakaguchi H; Nitanda H; Kaneko K; Yamazaki N; Yanagihara A; Taguchi R; Sakai F; Yasuda M; Kobayashi K
Lung Cancer; 2019 Mar; 129():16-21. PubMed ID: 30797486
[TBL] [Abstract][Full Text] [Related]
9. Assessment of epidermal growth factor receptor mutation by endobronchial ultrasound-guided transbronchial needle aspiration.
Nakajima T; Yasufuku K; Suzuki M; Hiroshima K; Kubo R; Mohammed S; Miyagi Y; Matsukuma S; Sekine Y; Fujisawa T
Chest; 2007 Aug; 132(2):597-602. PubMed ID: 17573511
[TBL] [Abstract][Full Text] [Related]
10. Detection of epidermal growth factor receptor and human epidermal growth factor receptor 2 activating mutations in lung adenocarcinoma by high-resolution melting amplicon analysis: correlation with gene copy number, protein expression, and hormone receptor expression.
Willmore-Payne C; Holden JA; Layfield LJ
Hum Pathol; 2006 Jun; 37(6):755-63. PubMed ID: 16733218
[TBL] [Abstract][Full Text] [Related]
11. Diagnosis of metachronous multiple lung adenocarcinoma at the cut-end by epidermal growth factor receptor mutation status discordance 4 years after sublobar resection for adenocarcinoma in situ: report of a case.
Isaka T; Yokose T; Ito H; Imamura N; Watanabe M; Imai K; Nishii T; Yamada K; Nakayama H; Masuda M
Surg Today; 2015 Oct; 45(10):1330-4. PubMed ID: 25377270
[TBL] [Abstract][Full Text] [Related]
12. Pulmonary Adenocarcinoma In Situ and Minimally Invasive Adenocarcinomas in European Patients Have Less
Petterson J; Mustafa D; Bandaru S; Eklund EÄ; Hallqvist A; Sayin VI; Gagné A; Fagman H; Akyürek LM
Int J Mol Sci; 2024 Mar; 25(5):. PubMed ID: 38474205
[TBL] [Abstract][Full Text] [Related]
13. Immunostaining with EGFR mutation-specific antibodies: a reliable screening method for lung adenocarcinomas harboring EGFR mutation in biopsy and resection samples.
Fan X; Liu B; Xu H; Yu B; Shi S; Zhang J; Wang X; Wang J; Lu Z; Ma H; Zhou X
Hum Pathol; 2013 Aug; 44(8):1499-507. PubMed ID: 23465272
[TBL] [Abstract][Full Text] [Related]
14. Novel epidermal growth factor receptor mutation-specific antibodies for non-small cell lung cancer: immunohistochemistry as a possible screening method for epidermal growth factor receptor mutations.
Kato Y; Peled N; Wynes MW; Yoshida K; Pardo M; Mascaux C; Ohira T; Tsuboi M; Matsubayashi J; Nagao T; Ikeda N; Hirsch FR
J Thorac Oncol; 2010 Oct; 5(10):1551-8. PubMed ID: 20697298
[TBL] [Abstract][Full Text] [Related]
15. L858R EGFR mutation status correlated with clinico-pathological features of Japanese lung cancer.
Sasaki H; Endo K; Takada M; Kawahara M; Kitahara N; Tanaka H; Okumura M; Matsumura A; Iuchi K; Kawaguchi T; Yukiue H; Kobayashi Y; Yano M; Fujii Y
Lung Cancer; 2006 Oct; 54(1):103-8. PubMed ID: 16890322
[TBL] [Abstract][Full Text] [Related]
16. [Immunohistochemistry using epidermal growth factor receptor mutation-specific antibodies of delE746-A750 and L858R in lung adenocarcinomas].
Fan XS; Liu B; Yu B; Shi SS; Wang X; Zhang J; Wang JD; Lu ZF; Ma HH; Zhou XJ
Zhonghua Bing Li Xue Za Zhi; 2013 Mar; 42(3):173-7. PubMed ID: 23769436
[TBL] [Abstract][Full Text] [Related]
17. [Expression of epidermal growth factor receptor mutation specific antibodies in lung adenocarcinoma: evaluation of sensitivity, specificity and relationship to histologic subtypes].
Lai YM; Feng Q; Sun Y; Wang P; Shi YF; Zhao M; Wu Q; Li XH
Zhonghua Bing Li Xue Za Zhi; 2016 Sep; 45(9):606-11. PubMed ID: 27646888
[TBL] [Abstract][Full Text] [Related]
18. EGFR mutation-specific antibodies in pulmonary adenocarcinoma: a comparison with DNA direct sequencing.
Ambrosini-Spaltro A; Campanini N; Bortesi B; Azzoni C; Naldi N; Ampollini L; Tiseo M; Ardizzoni A; Rusca M; Carbognani P; Silini EM
Appl Immunohistochem Mol Morphol; 2012 Jul; 20(4):356-62. PubMed ID: 22710815
[TBL] [Abstract][Full Text] [Related]
19. Use of mutation specific antibodies to detect EGFR status in small biopsy and cytology specimens of lung adenocarcinoma.
Hasanovic A; Ang D; Moreira AL; Zakowski MF
Lung Cancer; 2012 Aug; 77(2):299-305. PubMed ID: 22542171
[TBL] [Abstract][Full Text] [Related]
20. Detection of epidermal growth factor receptor mutation in transbronchial needle aspirates of non-small cell lung cancer.
Horiike A; Kimura H; Nishio K; Ohyanagi F; Satoh Y; Okumura S; Ishikawa Y; Nakagawa K; Horai T; Nishio M
Chest; 2007 Jun; 131(6):1628-34. PubMed ID: 17565015
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
